Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study
Diseases of the Esophagus · 2023
DOI: 10.1093/dote/doad031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, 2023. Verfasst von Xing Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
High-quality evidence indicated that both neoadjuvant carboplatin/paclitaxel (CROSS) and cisplatin/5-fluorouracil (PF) regimens in combination with radiotherapy improve survival outcomes compared to surgery alone in patients with esophageal cancer. It is not yet known whether they may differ in terms of treatment burden and healthcare costs. A total of 232 Taiwanese patients with esophageal squamous cell carcinoma who had undergone neoadjuvant chemoradiotherapy (nCRT) with either the CROSS (n = 153) or the PF (n = 79) regimens were included. Hospital encounters and adverse events were assessed for determining treatment burden. Cost-effectiveness analysis was undertaken using the total costs incurred over 3 years in relation to overall survival (OS) and progression-free survival (PFS). Compared with PF, the CROSS regimen was associated with a lower treatment burden: shorter inpatient days on average (4.65 ± 10.05 vs. 15.14 ± 17.63 days; P < 0.001) and fewer admission requirements (70% of the patients were never admitted vs. 20% in the PF group; P < 0.001). Patients in the CROSS group experienced significantly less nausea, vomiting, and diarrhea. While the benefits observed in the CROSS group were associated with additional nCRT-related expenditures (1388 United States dollars [USD] of added cost per patient), this regimen remained cost-effective. At a willingness-to-pay threshold of 50,000 USD per life-year, the probability of the CROSS regimen to be more cost-effective than PF was 94.1% for PFS but decreased to 68.9% for OS. The use of the CROSS regimen for nCRT in patients with ESCC was associated with a lower treatment burden and was more cost-effective than PF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan.
- Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
- Division of Thoracic Surgery, Chang Gung Memorial Hospital-Kaohsiung, Chang Gung University, Kaohsiung, Taiwan.
- Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan.
- Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan.
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Gao, X., Yang, Z. H., Cheng, Y. H., Chi, C. L., Yang, T. Y., Chuang, K. H., Wu, C. E., van Lanschot, J. J., Wen, Y. W., & Chao, Y. K. (2023). Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus. https://doi.org/10.1093/dote/doad031
Vancouver
Gao X, Yang ZH, Cheng YH, Chi CL, Yang TY, Chuang KH, et al. Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus. 2023. doi:10.1093/dote/doad031
BibTeX
@article{Gao2023,
author = {Gao, Xing and Yang, Zhi-Hao and Cheng, Yi-Hsuan and Chi, Chun-Ling and Yang, Tzu-Yi and Chuang, Kai-Hao and Wu, Chiao-En and van Lanschot, Joseph Jan-Baptist and Wen, Yu-Wen and Chao, Yin-Kai},
title = {Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study},
journal = {Diseases of the Esophagus},
year = {2023},
doi = {10.1093/dote/doad031}
}
EUVIMED